spacer
home > ebr > summer 2017 > hidden treasures
PUBLICATIONS
European Biopharmaceutical Review

Hidden Treasures

Nowadays, both the EMA and FDA want to see treatments based on solid evidence, but how can we document this? For many different diseases, therapeutic effects seem to be poorly defined and challenging to monitor. Fighting a symptom, such as lowering the body’s temperature during a fever, does not count. Truly desirable effects that should be assessed or monitored would include killing bad bacteria in case of an infection, thus lowering the body’s bacterial load.

Usual Matrix Used

Each individual biomarker is part of one or more of seven categories, as defined by the FDA and National Institutes of Health Working Group, including diagnostic, monitoring, prognostic and safety. Biomarkers are endogenous substances, usually easiest to determine in blood plasma, saliva or urine. These bodily fluids are not difficult to obtain and derived from or connected to the bloodstream, which nourishes all organs and is also in contact with the central nervous system and the cerebrospinal fluid. This blood-brain barrier protects our control centre from the detrimental influences of a great number of large molecular substances, which are not able to cross it.

Historically, many may first think of protein biomarkers. Proteins may indeed be closer to the body’s reaction to a disease than small molecules. However, detecting these specific proteins in the blood is not always easy. We have many thousands of proteins in the body which consist of amino acids, and the sequence of the connected amino acids is responsible for the function of the protein.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Hermann Mascher, founder and Bioanalytical Consultant at pharm-analyt Labor, has more than 100 publications in peer-reviewed journals, including two books by Wiley-VCH. He is also the inventor of three patents for biomarkers in the area of rare lysosomal storage diseases: Gaucher, NPC and metachromatic leukodystrophy.
spacer
Professor Hermann Mascher
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Announces Success of Integrated Discovery Project with ENYO Pharma

Wilmington, Mass and Lyon, France, Nov. 28, 2017 - Charles River Laboratories International, Inc. (NYSE: CRL) and ENYO Pharma SA today announced the results of a successful collaboration. Together, the companies identified the mode of action of ENYO Pharma’s lead preclinical chemical series, EYP002, using Charles River’s newly acquired, molecular target identification tool: Capture Compound Mass Spectrometry (CCMS) technology.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

INTERPHEX 2018

17-18 April 2018, Javits Center, New York, USA

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA).
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement